Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


14 Items
Title  Creator  Group name  Publishing year 
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program Le Du et al. EquipeCTCS 2023-10-03
Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort Grinda et al. EquipeCTCS 2023-08
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer Delaloge et al. EquipePC 2022-05
Pregnancy, fertility concerns and fertility preservation procedures in a national study of French breast cancer survivors Mangiardi-Veltin et al. EquipeCTCS 2022-06
Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France de Calbiac et al. EquipePC 2022-09-01
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer Bortolini Silveira et al. EquipeCTCS 2021-09-09
Impact of body mass index on overall survival in patients with metastatic breast cancer Saleh et al. EquipePC 2021-02
Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort Pasquier et al. EquipeCTCS Jan 2020
Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14) Penault-Llorca et al. EquipeELC 2020-02
Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016 Deluche et al. EquipeCTCS 2020-04
Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer Delrieu et al. EquipeCTCS 2020-07-01
Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET) Vasseur et al. EquipeCTCS Nov 26, 2019
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort Darlix et al. EquipeCTCS Dec 2019
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort Gobbini et al. EquipeCTCS Jun 2018
14 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés